Kameshwar Prasad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Kameshwar Prasad has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
Amit Kumar
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
32 shared publications- Pradeep Kumar
Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India
27 shared publications - Shubham Misra
Department of Neurology, Yale School of Medicine, New Haven, CT
19 shared publications - Ram Sagar
Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
17 shared publications Deepti Vibha
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
13 shared publications- Deepti Vibha
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
12 shared publications
Latest Publications
- 13 October 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop)
Outcomes in Patients with Tuberculous Meningitis: A Prospective Cohort Study in North India
: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, carrying the highest mortality among all forms. This multicentric prospective cohort study conducted in North India aimed to determine the incidence of complications, functional outcome (modified Rankin scale [mRS]), and mortality in TBM. Patients 12 years old and older with TBM were followed up until completion of 9 months of antitubercular treatment. Patients with concomitant HIV infection, other infections causing meningitis, or multidrug-resistant tuberculosis were excluded. The primary outcome was mRS at 9 months. Secondary outcomes included mRS at 6 months, poor mRS (>2), Barthel Index, and mortality at 6 and 9 months. Between October 1, 2019 and March 31, 2024, 585 eligible patients were enrolled, of whom 495 (84.6%) completed follow-up. The median age was 24.0 years old, and the majority were female ( n = 304/495; 61.4%). Complications were present in 377 patients (76.2%): focal neurological deficits (41.6%), seizures (38.6%), immune reconstitution inflammatory syndrome (32.7%), hydrocephalus (24.8%), and drug-induced liver injury (14.1%). Complications were associated with worse mRS on unadjusted analysis (odds ratio [OR]: 2.5 [1.7–3.7]; P P = 0.30). The median mRS improved from 4.0 at presentation to 2.0 at 6 months and 1.0 at 9 months. Death occurred at a median of 91.0 days after presentation. Mortality at 6 months was 9.3% and at 9 months was 10.7%.
- 13 October 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. -1 (aop)
Outcomes in Patients with Tuberculous Meningitis: A Prospective Cohort Study in North India
: Tuberculous meningitis (TBM) is the most severe form of extrapulmonary tuberculosis, carrying the highest mortality among all forms. This multicentric prospective cohort study conducted in North India aimed to determine the incidence of complications, functional outcome (modified Rankin scale [mRS]), and mortality in TBM. Patients 12 years old and older with TBM were followed up until completion of 9 months of antitubercular treatment. Patients with concomitant HIV infection, other infections causing meningitis, or multidrug-resistant tuberculosis were excluded. The primary outcome was mRS at 9 months. Secondary outcomes included mRS at 6 months, poor mRS (>2), Barthel Index, and mortality at 6 and 9 months. Between October 1, 2019 and March 31, 2024, 585 eligible patients were enrolled, of whom 495 (84.6%) completed follow-up. The median age was 24.0 years old, and the majority were female ( n = 304/495; 61.4%). Complications were present in 377 patients (76.2%): focal neurological deficits (41.6%), seizures (38.6%), immune reconstitution inflammatory syndrome (32.7%), hydrocephalus (24.8%), and drug-induced liver injury (14.1%). Complications were associated with worse mRS on unadjusted analysis (odds ratio [OR]: 2.5 [1.7–3.7]; P P = 0.30). The median mRS improved from 4.0 at presentation to 2.0 at 6 months and 1.0 at 9 months. Death occurred at a median of 91.0 days after presentation. Mortality at 6 months was 9.3% and at 9 months was 10.7%.
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 457-458
Response to Prof. Jose Berciano’s Letter to the Editor on “Intravenous Methylprednisolone in Guillain–Barré Syndrome: The Way Forward?”
An abstract is unavailable. This article is available as a PDF only.
- 1 May 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (3) , 457-458
Open AccessResponse to Prof. Jose Berciano’s Letter to the Editor on “Intravenous Methylprednisolone in Guillain–Barré Syndrome: The Way Forward?”
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 March 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (2) , 180-181
Intravenous Methylprednisolone in Guillain–Barré Syndrome: The Way Forward
- 1 March 2025
- Published by Wolters Kluwer Health in Annals of Indian Academy of Neurology
- Vol. 28 (2) , 180-181
Open AccessIntravenous Methylprednisolone in Guillain–Barré Syndrome: The Way Forward
- 24 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 962-966
Evaluation of Efficacy of Short Message Service (SMS) Reminders in Improving Adherence to Laboratory Monitoring in Patients on Anticoagulation with Vitamin K antagonists(VKA): A Randomized Controlled Trial
The aim of the study was to assess whether SMS reminders to patients on Vit K antagonists(VKA) improved adherence to INR testing as compared to clinic based follow up. The study was a parallel group randomized open label single center study carried out at a tertiary care hospital in North India from Oct 2018 to Nov 2019. The interventional arm received SMS in Hindi or English on two consecutive days prior to scheduled INR testing. Primary outcome was percentage of patients adhering to regular INR testing in two groups. Secondary outcomes included time in therapeutic range(TTR) for each patient and proportion of patients having TTR of more than 60% by percentage method. 111 patients were screened and 98 were randomized into two groups (49 each group). In the control group 13(26.5%) as compared to 32(78%) in the intervention group were adherent to regular INR testing, the result was statistically significant (p 60% as compared to 24(48.9%) in interventional arm and the result was statistically significant (RR 1.96). In our study we found that regular SMS reminders to patients on Vit K antagonists result in better adherence to regular INR testing.
- 24 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 962-966
Evaluation of Efficacy of Short Message Service (SMS) Reminders in Improving Adherence to Laboratory Monitoring in Patients on Anticoagulation with Vitamin K antagonists(VKA): A Randomized Controlled Trial
The aim of the study was to assess whether SMS reminders to patients on Vit K antagonists(VKA) improved adherence to INR testing as compared to clinic based follow up. The study was a parallel group randomized open label single center study carried out at a tertiary care hospital in North India from Oct 2018 to Nov 2019. The interventional arm received SMS in Hindi or English on two consecutive days prior to scheduled INR testing. Primary outcome was percentage of patients adhering to regular INR testing in two groups. Secondary outcomes included time in therapeutic range(TTR) for each patient and proportion of patients having TTR of more than 60% by percentage method. 111 patients were screened and 98 were randomized into two groups (49 each group). In the control group 13(26.5%) as compared to 32(78%) in the intervention group were adherent to regular INR testing, the result was statistically significant (p 60% as compared to 24(48.9%) in interventional arm and the result was statistically significant (RR 1.96). In our study we found that regular SMS reminders to patients on Vit K antagonists result in better adherence to regular INR testing.
- Open Access
- 3 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0296616
Prognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms
Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical for patient care. We aim to investigate protein biomarkers’ role in prognosticating outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N = 150). We defined poor outcomes as modified Rankin scale score of 3–6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic regression, UCH-L1 (adjusted OR 9.23; 95%CI 2.41–35.33), alpha-2-macroglobulin (aOR 5.57; 95%CI 1.26–24.59), and Serpin-A11 (aOR 9.33; 95%CI 1.09–79.94) were independent predictors of 90-day poor outcome; MMP-2 (aOR 6.32; 95%CI 1.82–21.90) was independent predictor of 180-day poor outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 95%CI 1.24–3.48) predicted 90-day and MMP-9 (aOR 1.98; 95%CI 1.19–3.32) predicted 180-day mortality. Machine learning identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, APO-C1, and MMP-2 for mortality prediction. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted short-term poor outcomes and mortality after ICH. Further research utilizing a multi-omics platform and temporal profiling is needed to explore additional biomarkers and refine predictive models for ICH prognosis.
- 3 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0296616
Open AccessPrognostic biomarkers of intracerebral hemorrhage identified using targeted proteomics and machine learning algorithms
Early prognostication of patient outcomes in intracerebral hemorrhage (ICH) is critical for patient care. We aim to investigate protein biomarkers’ role in prognosticating outcomes in ICH patients. We assessed 22 protein biomarkers using targeted proteomics in serum samples obtained from the ICH patient dataset (N = 150). We defined poor outcomes as modified Rankin scale score of 3–6. We incorporated clinical variables and protein biomarkers in regression models and random forest-based machine learning algorithms to predict poor outcomes and mortality. We report Odds Ratio (OR) or Hazard Ratio (HR) with 95% Confidence Interval (CI). We used five-fold cross-validation and bootstrapping for internal validation of prediction models. We included 149 patients for 90-day and 144 patients with ICH for 180-day outcome analyses. In multivariable logistic regression, UCH-L1 (adjusted OR 9.23; 95%CI 2.41–35.33), alpha-2-macroglobulin (aOR 5.57; 95%CI 1.26–24.59), and Serpin-A11 (aOR 9.33; 95%CI 1.09–79.94) were independent predictors of 90-day poor outcome; MMP-2 (aOR 6.32; 95%CI 1.82–21.90) was independent predictor of 180-day poor outcome. In multivariable Cox regression models, IGFBP-3 (aHR 2.08; 95%CI 1.24–3.48) predicted 90-day and MMP-9 (aOR 1.98; 95%CI 1.19–3.32) predicted 180-day mortality. Machine learning identified additional predictors, including haptoglobin for poor outcomes and UCH-L1, APO-C1, and MMP-2 for mortality prediction. Overall, random forest models outperformed regression models for predicting 180-day poor outcomes (AUC 0.89), and 90-day (AUC 0.81) and 180-day mortality (AUC 0.81). Serum biomarkers independently predicted short-term poor outcomes and mortality after ICH. Further research utilizing a multi-omics platform and temporal profiling is needed to explore additional biomarkers and refine predictive models for ICH prognosis.
- Open Access
- 1 May 2024
- Published by Medknow in Annals of Indian Academy of Neurology
- Vol. 27 (3) , 236-243
Prevalence and Risk Factors of Cerebral Microbleeds in Community-Dwelling Adults in Urban Delhi
Background: Several observational studies have reported the prevalence of cerebral microbleeds (CMBs) and their risk factors in an elderly population. Any information in this regard is currently lacking from India. Aim of this study was to estimate the prevalence, risk factors of CMBs, and association with cognition in an Indian urban population aged 50 years and above. Methods: Household surveys were conducted as part of ongoing Longitudinal Cognition and Aging Research on Population of the National Capital Region (LoCARPoN) study in areas of urban Delhi. Magnetic resonance imaging of the brain was performed in 2599 participants. Using standard neuropsychological battery, mean Z-scores for each domain (memory, executive, information) were derived. Binary and stepwise logistic regression models were used to determine associated risk factors for the presence of CMB and its association with cognitive domains. Results: The prevalence of CMBs was 14.42% (95% confidence interval [CI]: 13.06–15.73). Of these, 203 (7.81%) participants had single CMBs and 172 (6.61%) had multiple microbleeds (≥2). Higher prevalence was observed in older age (60–70 years: odds ratio [OR]: 1.25 [95% CI: 0.93–1.67]; 70–80 years: OR: 2.05 [95% CI: 1.48–2.84]; ≥80 years: OR: 3.27 [95% CI: 1.97–5.44]) compared to individuals in the age group 50–60 years. History of stroke (OR: 2.97 [95% CI: 1.56–5.66]), hypertension (OR: 1.36 [95% CI: 1.05–1.75]), and smoking (OR: 1.43 [95% CI: 1.11–1.85]) was associated with at least one CMB. Multiple CMBs were associated with worse scores in memory and executive domains. Conclusion: Older age, hypertension, history of stroke, and history of smoking emerged as important risk factors for the presence of multiple CMBs. Follow-up study is required to determine implications of CMBs.
- 1 May 2024
- Published by Medknow in Annals of Indian Academy of Neurology
- Vol. 27 (3) , 236-243
Open AccessPrevalence and Risk Factors of Cerebral Microbleeds in Community-Dwelling Adults in Urban Delhi
Background: Several observational studies have reported the prevalence of cerebral microbleeds (CMBs) and their risk factors in an elderly population. Any information in this regard is currently lacking from India. Aim of this study was to estimate the prevalence, risk factors of CMBs, and association with cognition in an Indian urban population aged 50 years and above. Methods: Household surveys were conducted as part of ongoing Longitudinal Cognition and Aging Research on Population of the National Capital Region (LoCARPoN) study in areas of urban Delhi. Magnetic resonance imaging of the brain was performed in 2599 participants. Using standard neuropsychological battery, mean Z-scores for each domain (memory, executive, information) were derived. Binary and stepwise logistic regression models were used to determine associated risk factors for the presence of CMB and its association with cognitive domains. Results: The prevalence of CMBs was 14.42% (95% confidence interval [CI]: 13.06–15.73). Of these, 203 (7.81%) participants had single CMBs and 172 (6.61%) had multiple microbleeds (≥2). Higher prevalence was observed in older age (60–70 years: odds ratio [OR]: 1.25 [95% CI: 0.93–1.67]; 70–80 years: OR: 2.05 [95% CI: 1.48–2.84]; ≥80 years: OR: 3.27 [95% CI: 1.97–5.44]) compared to individuals in the age group 50–60 years. History of stroke (OR: 2.97 [95% CI: 1.56–5.66]), hypertension (OR: 1.36 [95% CI: 1.05–1.75]), and smoking (OR: 1.43 [95% CI: 1.11–1.85]) was associated with at least one CMB. Multiple CMBs were associated with worse scores in memory and executive domains. Conclusion: Older age, hypertension, history of stroke, and history of smoking emerged as important risk factors for the presence of multiple CMBs. Follow-up study is required to determine implications of CMBs.
- 6 December 2023
- Published by Springer Nature in Sleep and Breathing
- Vol. 28 (2) , 975-987
Association of obstructive sleep apnea and sleep quality with cognitive function: a study of middle-aged and elderly persons in India
Introduction Symptoms of obstructive sleep apnea (OSA) and poor sleep quality affect around one in ten people in India. We aimed to determine if OSA symptoms and poor sleep quality are independently associated with cognition in middle-aged and elderly urban Indian populations. Methods We studied the cross-sectional association between OSA symptoms (by Berlin Questionnaire), poor sleep quality (by Pittsburgh Sleep Quality Index), and cognitive function in adults ≥ 50 years. Using a standard neuropsychological battery for cognitive function, a G-factor was derived as the first rotated principal component assessing domains of information processing, memory, and executive function. The associations of exposures with cognitive measures were modeled using linear regression, adjusted for metabolic risk factors, lifestyle factors, and psychosocial problems, followed by stratified analysis by decadal age group. Results A total of 7505 adults were enrolled. Excluding those with MMSE < 26 (n 710), of 6795 individuals (49.2% women), mean (SD) age 64.2 (9.0) years, 38.3% had high risk of OSA symptoms, and 15.9% had poor sleep quality. OSA symptoms were negatively associated with cognitive domains of information processing (adjusted beta coefficient of z-score − 0.02, p-value 0.006), memory (− 0.03, 0.014), and G-factor (− 0.11, 0.014) in full-model. Stratified analysis by age group showed significant adverse effects of OSA symptoms on cognition for middle-aged people (50–60 years) (− 0.26, 0.001), but not in later age groups. Poor sleep quality was also associated with lower cognitive scores for G-factor (− 0.48, < 0.001), memory (− 0.08, 0.005), and executive domains (− 0.12, < 0.001), but not with information domain. Conclusion The findings suggest that both symptoms of OSA and poor sleep quality have a direct adverse impact on cognition in an Indian setting. A modest effect of age on the relationship of OSA and cognition was also observed.
- 6 December 2023
- Published by Springer Nature in Sleep and Breathing
- Vol. 28 (2) , 975-987
Association of obstructive sleep apnea and sleep quality with cognitive function: a study of middle-aged and elderly persons in India
Introduction Symptoms of obstructive sleep apnea (OSA) and poor sleep quality affect around one in ten people in India. We aimed to determine if OSA symptoms and poor sleep quality are independently associated with cognition in middle-aged and elderly urban Indian populations. Methods We studied the cross-sectional association between OSA symptoms (by Berlin Questionnaire), poor sleep quality (by Pittsburgh Sleep Quality Index), and cognitive function in adults ≥ 50 years. Using a standard neuropsychological battery for cognitive function, a G-factor was derived as the first rotated principal component assessing domains of information processing, memory, and executive function. The associations of exposures with cognitive measures were modeled using linear regression, adjusted for metabolic risk factors, lifestyle factors, and psychosocial problems, followed by stratified analysis by decadal age group. Results A total of 7505 adults were enrolled. Excluding those with MMSE < 26 (n 710), of 6795 individuals (49.2% women), mean (SD) age 64.2 (9.0) years, 38.3% had high risk of OSA symptoms, and 15.9% had poor sleep quality. OSA symptoms were negatively associated with cognitive domains of information processing (adjusted beta coefficient of z-score − 0.02, p-value 0.006), memory (− 0.03, 0.014), and G-factor (− 0.11, 0.014) in full-model. Stratified analysis by age group showed significant adverse effects of OSA symptoms on cognition for middle-aged people (50–60 years) (− 0.26, 0.001), but not in later age groups. Poor sleep quality was also associated with lower cognitive scores for G-factor (− 0.48, < 0.001), memory (− 0.08, 0.005), and executive domains (− 0.12, < 0.001), but not with information domain. Conclusion The findings suggest that both symptoms of OSA and poor sleep quality have a direct adverse impact on cognition in an Indian setting. A modest effect of age on the relationship of OSA and cognition was also observed.
- 1 May 2023
- Published by Medknow in Neurology India
- Vol. 71 (3) , 514-521
Rivastigmine for Cognitive Impairment in Multiple Sclerosis
Background and Objective: Nearly 40–65% patients with MS develop cognitive impairment during the disease. There is no treatment clearly effective in improving the cognitive deficits. To evaluate the efficacy and safety of Rivastigmine in cognitively impaired MS patients. Materials and Methods: This was a parallel group randomized open label study with blinded end-point assessment. The patient allocation to treatment and control arm was done by telephonic contact with an independent statistician who used a computer to generate a random sequence of allocation using permuted block randomization (varying block size of 4 and 6) in 1:1 ratio. The outcome assessor was blinded to this allocation. A total of 60 patients were in included in the study (30 in each arm). Primary outcome was improvement in memory functions (using logical memory subset of Wechsler Memory Scale III, India) assessed after 12 weeks. Secondary outcomes included fatigue, depression, and safety. Results: In modified intention to treat analysis (N = 22), treatment arm showed statistically significant improvement in memory function with mean difference of 7.56 [95% CI (0.67,14.46), p 0.032] as compared to control arm. There was no statistically significant difference in outcomes such as fatigue and depression. Vomiting was the most common side effect. No major adverse events were observed in either group. Conclusion: Rivastigmine is safe and effective in improving memory functions in cognitively impaired MS patients. However, our study has a small sample size and tested only a single domain. Larger studies with a validated single comprehensive neuropsychological test are needed.
- 1 May 2023
- Published by Medknow in Neurology India
- Vol. 71 (3) , 514-521
Rivastigmine for Cognitive Impairment in Multiple Sclerosis
Background and Objective: Nearly 40–65% patients with MS develop cognitive impairment during the disease. There is no treatment clearly effective in improving the cognitive deficits. To evaluate the efficacy and safety of Rivastigmine in cognitively impaired MS patients. Materials and Methods: This was a parallel group randomized open label study with blinded end-point assessment. The patient allocation to treatment and control arm was done by telephonic contact with an independent statistician who used a computer to generate a random sequence of allocation using permuted block randomization (varying block size of 4 and 6) in 1:1 ratio. The outcome assessor was blinded to this allocation. A total of 60 patients were in included in the study (30 in each arm). Primary outcome was improvement in memory functions (using logical memory subset of Wechsler Memory Scale III, India) assessed after 12 weeks. Secondary outcomes included fatigue, depression, and safety. Results: In modified intention to treat analysis (N = 22), treatment arm showed statistically significant improvement in memory function with mean difference of 7.56 [95% CI (0.67,14.46), p 0.032] as compared to control arm. There was no statistically significant difference in outcomes such as fatigue and depression. Vomiting was the most common side effect. No major adverse events were observed in either group. Conclusion: Rivastigmine is safe and effective in improving memory functions in cognitively impaired MS patients. However, our study has a small sample size and tested only a single domain. Larger studies with a validated single comprehensive neuropsychological test are needed.
- Open Access
- 28 April 2023
- Published by Elsevier in Aging Brain
- Vol. 3, 100075
Multimodal imaging of the aging brain: Baseline findings of the LoCARPoN study
- 28 April 2023
- Published by Elsevier in Aging Brain
- Vol. 3, 100075
Open AccessMultimodal imaging of the aging brain: Baseline findings of the LoCARPoN study
- 1 January 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (1) , 35-41
Carotid Intima-Media Thickness (cIMT) and Cognitive Performance
Introduction: Atherosclerosis has been shown to impact cognitive impairment, with most of the evidence originating from European, African, or East Asian populations that have employed carotid intima-media thickness (cIMT) as a biomarker for atherosclerosis. Vascular disease is related to dementia/cognitive decline. There is no community-based study from India that has looked at the association of cIMT with cognitive performance. Methods: In this cross-sectional study between December 2014 and 2019, we recruited 7505 persons [(mean age 64.6 (9.2) y) and 50.9% women] from a community-dwelling population in New Delhi. These persons underwent carotid ultrasound to quantify cIMT and a cognitive test battery that tapped into memory, processing speed, and executive function. We also computed the general cognitive factor (g-factor), which was identified as the first unrotated component of the principal component analysis and explained 37.4% of all variances in the cognitive tests. We constructed multivariate linear regression models adjusted for age, sex, education, and cardiovascular risk factors. Additional adjustment was made for depression, anxiety, and psychosocial support in the final model. Results: We found a significant association of higher cIMT with worse performance in general cognition (β=−0. 01(95% CI: −0.01; −0.01); PP=0.003), memory (β=−0.29; 95% CI: −0.53; −0.05); P=0.016), and executive function (β=−0.54; 95% CI: −0.75; −0.33); P=<0.001). There was no statistically significant association of cIMT with Mini-Mental Status Examination score (β=0.02; 95% CI: −0.34; 0.40; 0.89). Conclusion: The cross-sectional study found significant associations of increased cIMT with worse performance in global cognition, information processing, memory, and executive function.
- 1 January 2023
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 37 (1) , 35-41
Carotid Intima-Media Thickness (cIMT) and Cognitive Performance
Introduction: Atherosclerosis has been shown to impact cognitive impairment, with most of the evidence originating from European, African, or East Asian populations that have employed carotid intima-media thickness (cIMT) as a biomarker for atherosclerosis. Vascular disease is related to dementia/cognitive decline. There is no community-based study from India that has looked at the association of cIMT with cognitive performance. Methods: In this cross-sectional study between December 2014 and 2019, we recruited 7505 persons [(mean age 64.6 (9.2) y) and 50.9% women] from a community-dwelling population in New Delhi. These persons underwent carotid ultrasound to quantify cIMT and a cognitive test battery that tapped into memory, processing speed, and executive function. We also computed the general cognitive factor (g-factor), which was identified as the first unrotated component of the principal component analysis and explained 37.4% of all variances in the cognitive tests. We constructed multivariate linear regression models adjusted for age, sex, education, and cardiovascular risk factors. Additional adjustment was made for depression, anxiety, and psychosocial support in the final model. Results: We found a significant association of higher cIMT with worse performance in general cognition (β=−0. 01(95% CI: −0.01; −0.01); PP=0.003), memory (β=−0.29; 95% CI: −0.53; −0.05); P=0.016), and executive function (β=−0.54; 95% CI: −0.75; −0.33); P=<0.001). There was no statistically significant association of cIMT with Mini-Mental Status Examination score (β=0.02; 95% CI: −0.34; 0.40; 0.89). Conclusion: The cross-sectional study found significant associations of increased cIMT with worse performance in global cognition, information processing, memory, and executive function.